补肾活血类中药治疗排卵障碍性不孕的系统评价(4)
[Abstract] To evaluate clinical studies on effect of traditional Chinese medicines in treating ovulatory disorder infertility by using evidence-based medical method. According to the standard of Cochrane Handbook， the selection standard of the randomized controlled clinical trail on kidney-tonifying and blood-activating traditional Chinese medicines in the treatment of ovulatory disorder infertility was formulated. Literatures in line with the standard were searched through computers among Chinese and English databases. The literatures included were evaluated by evidence-based medicine method， and analyzed with Revman 5. 1. There were 19 articles in line with the standard. Data for pregnancy rate， ovulation rate and miscarriage rate was extracted from them， and heterogeneity test was conducted with Meta， which showed no statistical heterogeneity. Results showed pregnancy rate (n=17)， RRP 1. 66， 95% Cl[1.45，1.92]， Z 7.06 (P<0.000 01)； ovulation rate (n=11)， RRO 1.05， 95% Cl[0.97，1.12]， Z 1.25 (P=0.21)； miscarriage rate (n=5)， RRM 0.24， 95% Cl[0.11，0.56]， Z 3.33 (P=0.000 9).After analysis and comparison， it is found that the Chinese medical treatment group was superior to the Western medicine control group in terms of pregnancy rate， which showed statistic significance.Both groups showed no obvious difference in the ovulation rate， and no statistic significance； the miscarriage rate of the Chinese medicine group is obviously lower than that of the Western medicine control group， which indicated statistic significances.This study preliminarily proves the good efficacy and unique advantages of kidney-tonifying and blood-activating traditional Chinese medicines in treating ovulatory disorder infertility.
[Key words] kidney-tonifying and blood-activating； ovulatory disorder infertility； systematic evaluation； randomized controlled trial (RCT)
doi：10.4268/cjcmm20131933, 百拇医药(范晓迪 马堃 单婧 金炫廷)
[Key words] kidney-tonifying and blood-activating； ovulatory disorder infertility； systematic evaluation； randomized controlled trial (RCT)
doi：10.4268/cjcmm20131933, 百拇医药(范晓迪 马堃 单婧 金炫廷)